PURPOSE: This study aimed to assess the safety, pharmacokinetic and activity profiles of the human-mouse chimeric monoclonal anti-disialoganglioside GD2 antibody ch14.18 produced in Chinese hamster ovary (CHO) cells (ch14.18/CHO). METHODS: Sixteen children with recurrent/refractory neuroblastoma (median age 7.6 y) were enrolled in this Phase 1 dose-finding study. Patients received ch14.18/CHO courses of 10, 20 or 30 mg/m (2)/day as an eight-hour infusion over five consecutive days. Three courses at the same dose level were allowed unless disease progressed. Clearance and biodistribution of radiolabelled ch14.18/CHO in Balb/c and A/J mice were analyzed. RESULTS: A total of 41 ch14.18/CHO courses were given (10 × 3 courses, 5 × 2 courses, 1 × 1 course). Side effects were similar in expectedness, frequency and magnitude to those reported for ch14.18/SP2/0. The dose level of 20 mg/m(2)/day was confirmed. Toxicity was reversible and no treatment-related deaths occurred. In children, the peak plasma concentration was 16.51 µg/ml ± 5.9 µg/ml and the half-life was 76.91 h ± 52.5 h. A partial response following ch14.18/CHO was observed in 2/7 patients with residual disease. In mice, the half-lives were 22.7 h ± 1.9h for ch14.18/CHO and 25.0 h ± 1.9 h for ch14.18/SP2/0. The biodistribution of (125)I-ch14.18/CHO in mice with neuroblastoma was identical to (125)I-ch14.18/SP2/0, indicating GD 2 targeting activity in vivo. Ch14.18 produced in CHO cells showed an unchanged toxicity profile and pharmacokinetics in neuroblastoma patients compared with ch14.18 produced in SP2/0 cells, and evidence of clinical activity was observed. In mice, analysis of pharmacokinetics and biodistribution showed comparable results between ch14.18/CHO and ch14.18/SP2/0. Based on these results, ch14.18/CHO was accepted for prospective clinical evaluation.
PURPOSE: This study aimed to assess the safety, pharmacokinetic and activity profiles of the human-mouse chimeric monoclonal anti-disialoganglioside GD2 antibody ch14.18 produced in Chinese hamster ovary (CHO) cells (ch14.18/CHO). METHODS: Sixteen children with recurrent/refractory neuroblastoma (median age 7.6 y) were enrolled in this Phase 1 dose-finding study. Patients received ch14.18/CHO courses of 10, 20 or 30 mg/m (2)/day as an eight-hour infusion over five consecutive days. Three courses at the same dose level were allowed unless disease progressed. Clearance and biodistribution of radiolabelled ch14.18/CHO in Balb/c and A/J mice were analyzed. RESULTS: A total of 41 ch14.18/CHO courses were given (10 × 3 courses, 5 × 2 courses, 1 × 1 course). Side effects were similar in expectedness, frequency and magnitude to those reported for ch14.18/SP2/0. The dose level of 20 mg/m(2)/day was confirmed. Toxicity was reversible and no treatment-related deaths occurred. In children, the peak plasma concentration was 16.51 µg/ml ± 5.9 µg/ml and the half-life was 76.91 h ± 52.5 h. A partial response following ch14.18/CHO was observed in 2/7 patients with residual disease. In mice, the half-lives were 22.7 h ± 1.9h for ch14.18/CHO and 25.0 h ± 1.9 h for ch14.18/SP2/0. The biodistribution of (125)I-ch14.18/CHO in mice with neuroblastoma was identical to (125)I-ch14.18/SP2/0, indicating GD 2 targeting activity in vivo. Ch14.18 produced in CHO cells showed an unchanged toxicity profile and pharmacokinetics in neuroblastomapatients compared with ch14.18 produced in SP2/0 cells, and evidence of clinical activity was observed. In mice, analysis of pharmacokinetics and biodistribution showed comparable results between ch14.18/CHO and ch14.18/SP2/0. Based on these results, ch14.18/CHO was accepted for prospective clinical evaluation.
Entities:
Keywords:
anti GD2; ch14.18/CHO; immunotherapy; monoclonal antibody; neuroblastoma
Authors: G Riethmüller; E Holz; G Schlimok; W Schmiegel; R Raab; K Höffken; R Gruber; I Funke; H Pichlmaier; H Hirche; P Buggisch; J Witte; R Pichlmayr Journal: J Clin Oncol Date: 1998-05 Impact factor: 44.544
Authors: N K Cheung; B H Kushner; I Y Cheung; K Kramer; A Canete; W Gerald; M A Bonilla; R Finn; S J Yeh; S M Larson Journal: J Clin Oncol Date: 1998-09 Impact factor: 44.544
Authors: M F Ozkaynak; P M Sondel; M D Krailo; J Gan; B Javorsky; R A Reisfeld; K K Matthay; G H Reaman; R C Seeger Journal: J Clin Oncol Date: 2000-12-15 Impact factor: 44.544
Authors: Thorsten Simon; Barbara Hero; Andreas Faldum; Rupert Handgretinger; Martin Schrappe; Dietrich Niethammer; Frank Berthold Journal: J Clin Oncol Date: 2004-09-01 Impact factor: 44.544
Authors: A L Yu; M M Uttenreuther-Fischer; C S Huang; C C Tsui; S D Gillies; R A Reisfeld; F H Kung Journal: J Clin Oncol Date: 1998-06 Impact factor: 44.544
Authors: Irene Y Cheung; Brian H Kushner; Shakeel Modak; Ellen M Basu; Stephen S Roberts; Nai-Kong V Cheung Journal: Oncoimmunology Date: 2017-07-31 Impact factor: 8.110
Authors: Jennifer E Gains; Neil J Sebire; Veronica Moroz; Keith Wheatley; Mark N Gaze Journal: Eur J Nucl Med Mol Imaging Date: 2017-10-17 Impact factor: 9.236
Authors: Julia W Cohen; Srivandana Akshintala; Eli Kane; Helen Gnanapragasam; Brigitte C Widemann; Seth M Steinberg; Nirali N Shah Journal: Oncologist Date: 2020-01-14